Editas Medicine, Inc.

Editas Medicine, Inc.verified

EDIT

Price:

$5.63

Market Cap:

$463.00M

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In additio...[Read more]

Industry

Biotechnology

IPO Date

2016-02-03

Stock Exchange

NASDAQ

Ticker

EDIT

The PE Ratio as of May 2024 (TTM) for Editas Medicine, Inc. (EDIT) is -2.72

According to Editas Medicine, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.72. This represents a change of -47.06% compared to the average of -5.14 of the last 4 quarters.

Editas Medicine, Inc. (EDIT) Historical PE Ratio (quarterly & annually)

How has EDIT PE Ratio performed in the past?

The mean historical PE Ratio of Editas Medicine, Inc. over the last ten years is -12.21. The current -2.72 PE Ratio has changed 2.13% with respect to the historical average. Over the past ten years (40 quarters), EDIT's PE Ratio was at its highest in in the September 2020 quarter at 55.75. The PE Ratio was at its lowest in in the September 2018 quarter at -23.70.

Quarterly (TTM)
Annual

Average

-12.21

Median

-9.72

Minimum

-37.56

Maximum

-2.98

Editas Medicine, Inc. (EDIT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Editas Medicine, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 213.30%

Maximum Annual PE Ratio = -2.98

Minimum Annual Increase = -Infinity%

Minimum Annual PE Ratio = -37.56

Quarterly (TTM)
Annual
YearPE RatioChange
2023-5.0268.51%
2022-2.98-69.27%
2021-9.70-74.18%
2020-37.56213.30%
2019-11.9923.01%
2018-9.74-5.38%
2017-10.3091.39%
2016-5.38-39.63%
2015-8.91-56.60%
2014-20.53-Infinity%

Editas Medicine, Inc. (EDIT) Average PE Ratio

How has EDIT PE Ratio performed in the past?

The current PE Ratio of Editas Medicine, Inc. (EDIT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-5.90

5-year avg

-13.45

10-year avg

-12.21

Editas Medicine, Inc. (EDIT) PE Ratio vs. Peers

How is EDIT’s PE Ratio compared to its peers?

Editas Medicine, Inc.’s PE Ratio is greater than Beam Therapeutics Inc. (-14.75), greater than CRISPR Therapeutics AG (-20.81), less than Caribou Biosciences, Inc. (-2.30), less than Verve Therapeutics, Inc. (-2.23), greater than Intellia Therapeutics, Inc. (-4.89), greater than Prime Medicine, Inc. (-3.54), less than Vertex Pharmaceuticals Incorporated (29.35), less than Ginkgo Bioworks Holdings, Inc. (-1.55), less than Allogene Therapeutics, Inc. (-1.47), greater than Sana Biotechnology, Inc. (-5.65),

Build a custom stock screener for Editas Medicine, Inc. (EDIT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Editas Medicine, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Editas Medicine, Inc. (EDIT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Editas Medicine, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Editas Medicine, Inc.'s PE Ratio?

How is the PE Ratio calculated for Editas Medicine, Inc. (EDIT)?

What is the highest PE Ratio for Editas Medicine, Inc. (EDIT)?

What is the 3-year average PE Ratio for Editas Medicine, Inc. (EDIT)?

What is the 5-year average PE Ratio for Editas Medicine, Inc. (EDIT)?

How does the current PE Ratio for Editas Medicine, Inc. (EDIT) compare to its historical average?